Pooled Analysis of Filgotinib Trials in RA: Incidence and Risk Factors for VTE and MACE

November 5-9, 2020; Virtual Meeting
Pooled analysis of 7 phase II/III trials suggests that the investigational JAK inhibitor is associated with low rates of VTE and MACE, with no major safety signals among those with cardiovascular risk factors.
Format: Microsoft PowerPoint (.ppt)
File Size: 213 KB
Released: November 13, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
AbbVie Inc.
Gilead Sciences, Inc.
Sanofi Genzyme Corporation

Related Content

ACR 2020: ARCTIC REWIND on flare risk of TNF inhibitor taper and withdrawal among patients with rheumatoid arthritis (RA) and stable remission, as reported by CCO

Released: November 13, 2020

CCO highlights from Stanley Cohen, Sheetal Desai, Eric Ruderman on JAKs before and after DMARD failure, treat-to-target, shared decision making

Stanley B. Cohen, MD Sheetal Desai, MD, MSEd Eric M. Ruderman, MD Released: November 13, 2020

ACR 2020: SEAM-RA trial on switch to ETN or MTX monotherapy vs continued combination therapy in RA patients with stable remission, as reported by CCO

Released: November 12, 2020

San Antonio cohort study from ACR 2020 on potential cardiotoxicity of hydroxychloroquine in patients with rheumatoid arthritis (RA), as reported by CCO

Released: November 11, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue